Ballentine Partners LLC Purchases Shares of 10,741 Dynavax Technologies Co. (NASDAQ:DVAX)

Ballentine Partners LLC acquired a new position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,741 shares of the biopharmaceutical company’s stock, valued at approximately $137,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. XTX Topco Ltd acquired a new stake in Dynavax Technologies in the second quarter valued at approximately $184,000. Bank of Montreal Can boosted its holdings in shares of Dynavax Technologies by 15.2% in the 2nd quarter. Bank of Montreal Can now owns 994,632 shares of the biopharmaceutical company’s stock worth $11,309,000 after buying an additional 130,893 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of Dynavax Technologies in the 2nd quarter worth approximately $902,000. Millennium Management LLC bought a new position in shares of Dynavax Technologies during the 2nd quarter worth $17,615,000. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Dynavax Technologies by 6.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 67,854 shares of the biopharmaceutical company’s stock valued at $762,000 after buying an additional 4,069 shares in the last quarter. 96.96% of the stock is owned by institutional investors and hedge funds.

Dynavax Technologies Trading Down 0.5 %

NASDAQ DVAX opened at $12.74 on Monday. The stock has a 50 day simple moving average of $12.70 and a two-hundred day simple moving average of $11.74. Dynavax Technologies Co. has a fifty-two week low of $9.74 and a fifty-two week high of $14.10. The stock has a market cap of $1.67 billion, a P/E ratio of 98.01 and a beta of 1.34. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23.

Dynavax Technologies (NASDAQ:DVAX) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.02. The firm had revenue of $80.63 million during the quarter, compared to analyst estimates of $83.64 million. Dynavax Technologies had a return on equity of 3.19% and a net margin of 7.85%. During the same quarter in the prior year, the company earned $0.10 EPS. On average, analysts forecast that Dynavax Technologies Co. will post 0.2 earnings per share for the current year.

Wall Street Analysts Forecast Growth

DVAX has been the topic of a number of recent analyst reports. HC Wainwright increased their price target on shares of Dynavax Technologies from $29.00 to $31.00 and gave the stock a “buy” rating in a report on Tuesday, January 14th. StockNews.com upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday, January 14th.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.